Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Effect of EECP on Anterior Ischemic Optic Neuropathy (AION)

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2017 by First Affiliated Hospital, Sun Yat-Sen University
Information provided by (Responsible Party):
WenHui Zhu, First Affiliated Hospital, Sun Yat-Sen University Identifier:
First received: January 8, 2013
Last updated: March 29, 2017
Last verified: March 2017
Enhanced External Counterpulsation(EECP) therapy may promote the recovery of visual function by improving the blood perfusion of eyes. The present study aims to investigate the effect of EECP on Anterior Ischemic Optic Neuropathy.

Condition Intervention
Anterior Ischemic Optic Neuropathy
Device: Enhanced external counterpulsation
Drug: Aspirin

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Study of the Effect of EECP on Anterior Ischemic Optic Neuropathy

Resource links provided by NLM:

Further study details as provided by First Affiliated Hospital, Sun Yat-Sen University:

Primary Outcome Measures:
  • visual acuity [ Time Frame: 7 weeks ]

Secondary Outcome Measures:
  • Ophthalmic artery blood flow velocity [ Time Frame: 7 weeks ]

Other Outcome Measures:
  • Central retinal artery flow velocity [ Time Frame: 7 weeks ]

Estimated Enrollment: 40
Study Start Date: December 2012
Estimated Study Completion Date: March 2018
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Enhanced External conterpulsation
Enhanced external counterpulsation (EECP) is a noninvasive modality for the treatment of ischemic cardiovascular disease. EECP therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole.
Device: Enhanced external counterpulsation
EECP is performed for 1 hours every day, for a total of 36 hours.
Other Name: EECP
Drug: Aspirin
Standard drug therapy
Active Comparator: aspirin
The subjects with Anterior ischemic Optic Neuropathy received aspirin therapy.
Drug: Aspirin
Standard drug therapy

Detailed Description:
Patients with Anterior Ischemic Optic Neuropathy are randomized into two groups: one group receive standard medical treatment for ischemic optic neuropathy, the other group plus EECP therapy besides standard medical treatment.

Ages Eligible for Study:   40 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • ischemic optic neuropathy
  • within 1 month

Exclusion Criteria:

  • Hemorrhagic disease
  • thrombophlebitis or infection lesions
  • severe hypertensive patients
  • Atrial fibrillation
  • Aortic regurgitation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01768260

Contact: Yan Zhang, MD 862087755766 ext 8141

China, Guangdong
The First Affiliated Hospital of Sun Yat- sen University Recruiting
Guangzhou, Guangdong, China, 510080
Contact: Ling Zhang, MA    862087755766 ext 8035   
Sponsors and Collaborators
First Affiliated Hospital, Sun Yat-Sen University
Study Director: Yan Zhang, Professor First Affiliated Hospital of Sun Yat-sen University
  More Information

Responsible Party: WenHui Zhu, Oculist-in-charge, First Affiliated Hospital, Sun Yat-Sen University Identifier: NCT01768260     History of Changes
Other Study ID Numbers: Eye EECP-1
Study First Received: January 8, 2013
Last Updated: March 29, 2017
Individual Participant Data  
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by First Affiliated Hospital, Sun Yat-Sen University:
visual acuity
artery flow velocity
Enhanced External Counterpulsation
Optic Neuropathy

Additional relevant MeSH terms:
Peripheral Nervous System Diseases
Optic Nerve Diseases
Optic Neuropathy, Ischemic
Pathologic Processes
Neuromuscular Diseases
Nervous System Diseases
Cranial Nerve Diseases
Eye Diseases
Vascular Diseases
Cardiovascular Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Antipyretics processed this record on May 22, 2017